B-type natriuretic peptides: Applications for heart failure management in 2005

Internal Medicine Journal

Volumn 35, Issue 7, 2005, Pages 377-379

  Troughton, R W ^a   Richards, M ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; EDITORIAL; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FAILURE; HEART STRESS; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE RELEASE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PRACTICE GUIDELINES; PROGNOSIS;

EID: 21444442062     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2005.00867.x     Document Type: Editorial

References (30)

1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.
2. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.
3. Troughton RW, Richards AM, Yandle TG, Nicholls G. Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure. Circulation 2004; 109: e325-6; author reply: e325-6.
4. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-82.
5. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 2004; 43: 416-22.
6. Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993; 69: 414-17.
7. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.
8. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000; 343: 246-53.
9. Davis M, Espiner E, Richards G, Billings J, Town I, Neill A et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea Lancet 1994; 343: 440-44.
10. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
11. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-22.
12. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42: 728-35.
13. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003; 42: 1793-800.
14. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350: 647-54.
15. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
16. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004; 109: 3176-81.
17. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43: 1019-26.
18. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
19. Troughton RW, Richards AM, Nicholls MG. Individualized treatment of heart failure. Intern Med J 2001; 31: 138-41.
20. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635-41.
21. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-21.
22. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330: 625.
23. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1587-93.
24. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97: 1921-9.
25. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786-92.
26. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999; 138: 1126-32.
27. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-83.
28. Richards AM, Doughty R, Nicholls MG, Macmahon S, Ikram H, Sharpe N et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 1999; 99: 786-92.
29. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-30.
30. Jourdain P, Funck F, Gueffet P, LeHelloco H, Donal E, Aupetit JF et al. Benefit of BNP plasma levels for optimising therapy: the Systolic Heart Failure Treatment Supported by BNP Multicenter Randomised Trial (STARS-BNP). J Am Coll Cardiol 2005; 45 (suppl. A): 3A (abstract 1001-151).